The immune checkpoint inhibitor pembrolizumab has been shown to significantly benefit patients with MSI-high/dMMR metastatic colorectal cancer. In a presentation to the 2020 ASCO Virtual Scientific Program, Professor Thierry Andre from the Sorbonne University said the PD-1inhibitor should now be the standard of care in first line therapy. The KEYNOTE-177 study compared outcomes in 307 ...
Colorectal cancer: immunotherapy doubles PFS
By Mardi Chapman
3 Jun 2020